Evidence map›Paper›PMID 42304594›Full record

ArticleCancer reports (Hoboken, N.J.)2026

Assessment of Multiple Prognostic Scores in Patients With Metastatic Renal Cell Carcinoma Receiving First-Line, Immune-Based Combinations.

Hiromichi Sakurai, Masanobu Shiga, Shuya Kandori, Shota Takahashi, Akifumi Omiya, Tomoki Ishida, Kotoe Matsuda, Bunpei Isoda, Bryan J Mathis, Manabu Komine and 7 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hiromichi SakuraiDepartment of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID 0009-0004-1254-0001
Masanobu ShigaDepartment of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID 0000-0001-8610-0149
Shuya KandoriDepartment of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.ORCID 0000-0003-4621-8470
Shota TakahashiDepartment of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Akifumi OmiyaDepartment of Urology, Ibaraki Prefectural Central Hospital, Mito, Ibaraki, Japan.
Tomoki IshidaDepartment of Urology, Ibaraki Prefectural Central Hospital, Mito, Ibaraki, Japan.ORCID 0009-0009-1261-0766
Kotoe MatsudaDepartment of Urology, Hitachi General Hospital, Hitachi, Ibaraki, Japan.ORCID 0009-0004-6941-0750
Bunpei IsodaDepartment of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Bryan J MathisDepartment of Cardiovascular Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Manabu KomineDepartment of Urology, Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan.
Masahiro IinumaDepartment of Urology, National Hospital Organization Mito Medical Center, Mito, Ibaraki, Japan.
Akira JorakuDepartment of Urology, Ibaraki Prefectural Central Hospital, Mito, Ibaraki, Japan.
Hiromitsu NegoroDepartment of Urology, Hitachi General Hospital, Hitachi, Ibaraki, Japan.ORCID 0000-0003-1144-2755
Masakazu TsutsumiDepartment of Urology, Hitachi General Hospital, Hitachi, Ibaraki, Japan.
Takamitsu InoueDepartment of Urology, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan.
Jun MiyazakiDepartment of Urology, International University of Health and Welfare Narita Hospital, Narita, Chiba, Japan.
Hiroyuki NishiyamaDepartment of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.

Funding

Co-Creation Place Formation Support Program JPMJPF2017
6 · The paper itself

Abstract

backgroundCombination immunotherapy is widely used as first-line treatment for metastatic renal cell carcinoma (mRCC), but pretreatment prognostic stratification remains insufficiently established.

aimsTo evaluate the performance of various prognostic scores in the first-line treatment of metastatic renal cell carcinoma (mRCC) with combination immunotherapy. METHODS AND

resultsWe retrospectively analyzed 145 patients who started first-line combination immunotherapy at six institutions from December 2015 to February 2025. We calculated IMDC, LIPI, RMH, PMHI, GRIm, C-PLAN, mGPS, and Meet-URO scores and performed survival (PFS, OS) and ROC analyses (PD, ORR). Survival analyses also evaluated the prognostic ability of each score by concordance index. At a median follow-up period of 28.8 months, the median progression-free survival (PFS) was 35.1 months and the median overall survival (OS) was not reached. Kaplan-Meier analysis showed significant differences for all scores except between IMDC and C-PLAN (PFS) and IMDC and mGPS (OS). Among these, PMHI and RMH demonstrated superior results in the C-index. ROC analysis showed no score had prognostic value for PD or ORR.

conclusionPMHI and RMH may be useful prognostic scores for survival outcomes in mRCC patients treated with immunotherapy. However, their ability to predict treatment efficacy (ORR and PD) is limited and further research is needed.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellImmunotherapyKidney NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective Studiesbiomarkerscarcinomafirst‐lineimmune checkpoint inhibitorprognosisprognostic scorerenal cell

Identifiers

PMID42304594
PMCPMC13272634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.